Tamil Nadu

Biocon is a research-driven, global healthcare company with a strong matrix of capabilities along the biopharmaceutical value chain. Focusing on unmet medical needs in cancer, diabetes and inflammatory diseases, it offers novel therapies on a platform of affordable innovation. Biocon together with group companies employs more than 2500 employees with approxmimately Rs 1,000 crore turnover and is expected to grow further during the current financial year.

Religare Wellness (formerly, Fortis Healthworld) is a pioneering endeavor within India’s healthcare industry putting health solutions on the retail map. As a part of the vision of Fortis Healthcare and Religare Enterprises, Religare Wellness incorporates setting up of a Pan India World Class Retail Network of health stores that would provide comprehensive solutions under one roof.

At Roche, 80,000 people across 150 countries are pushing back the frontiers of healthcare. Working together, we’ve become one of the world’s leading research-focused healthcare groups. Our success is built on innovation, curiosity and diversity, and on seeing each other’s differences as an advantage. To innovate healthcare, Roche has ambitious plans to keep learning and growing – and is seeking people who have the same goals for themselves.

ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. We specialize in the strategic development, management and analysis of programs that support Clinical Development – from compound selection to Phase I - IV clinical studies

Laila group is inviting applications from dedicated scientist to become a part of new innovative and exploratory research program for developing molecules/Nutraceuticals /Botanical drugs for unmet medical needs.

Nest Provides Professional licensing services in all the countries for Healthcare, allied and life science Professionals who intend to work in that country.
Nest can act a bridging source to guide, mentor, oversee you licensing process. It acts a facilitator / coordinator in your licensure documentation process etc.

Post: Pharmacist

Orinova, A cosmeceutical division of Origo Pharmaceuticals Pvt. Ltd. Orinova objective is - Discover the beauty. We believe in bringing super specialty innovative cosmeceuticals products for discovering the beauty from inside.

About Author:
Hiren Sakhiya,
M.Sc in Clinical Research Management,
Prist University, Thanjavur,
India
*sakhiyahiren@gmail.com

ABSTRACT
Diabetes a chronic (lifelong) disease marked by high levels of sugar in the blood. Diabetes is a common disease in older age, affecting about one in five individuals. In 2000, according to the World Health Organization, at least 171 million people worldwide suffer from diabetes, or 2.8% of the population. Its incidence is increasing rapidly, and it is estimated that by 2030, this number will almost double. Diabetes is also associated with mortality and significant morbidity, including neurological disability. Diabetes affects both peripheral nervous system and central nervous system. Neuropathy along with retinopathy and nephropathy appears in late stage of diabetes but effect on cognition starts in early stage of diabetes. Although the effects of diabetes on the peripheral nervous system are well established, the effects of diabetes on the central nervous system have been less clear. Several studies have found that diabetes is related to dementia and cognitive function. It is unclear in which stage of diabetes the cognitive decrements become manifest and how they progress over time. Study is conducted to confirm the association of cognitive function with diabetes.

About Authors:
Yamini Pendyala*, Sudha Talasila, M.sulthana
Department of Pharmaceutics,
Padmavathi College of Pharmacy and Research Institute,
Periyanahalli, Tamilnadu.
*Yamini.pendyala45@gmail.com

ABSTRACT
The purpose of this research was to formulate and systemically evaluate in-vitro and in-vivo performances of mucoadhesive Ramipril microspheres for its potential use in the treatment of hypertension, myocardial infraction. Ramipril mucoadhesive microspheres, containing chitosan as mucoadhesive polymer and ethyl cellulose as carrier polymer, were prepared by an emulsion-solvent evaporation technique. Preformulation studies were carried out before formulation design. Total seven formulations were prepared.Microspheres were discrete, spherical, free-flowing and showed a good percentage of drug entrapment efficiency. An in-vitro wash off test showed that Ramipril mucoadhesive microspheres adhered more strongly to the gastric mucous layer and could be retained in the gastrointestinal tract for an extended period of time. In-vitro dissolution test was carried out by using phosphate buffer pH 6.8. All the formulations showed good dissolution profiles. Among all the formulation F5 showed good dissolution profile with 81.0% of drug release in 12 hours. In-vitro release kinetic data of Ramipril microspheres showed that the drug release mechanism was diffusion controlled as the plots of Higuichi model was linear. All formulations exhibited Non-Fickian diffusion (n value is in between 0.5 to 1) mechanism. Stability studies were done for the selected formulation indicates that there is no change in drug content of the formulation.The results showed a sustained anti-hypertensive effect over a longer period of time in case of mucoadhesive microspheres, compared to the powder. In conclusion, the prolonged gastrointestinal residence time and slow release of Ramipril resulting from the mucoadhesive microspheres, could contribute to the provision of a sustained anti-hypertensive effect.